A novel class of highly potent multidrug resistance reversal agents: Disubstituted adamantyl derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 18, 2009, Pages 5376-5379

  Min, Kyung Hoon ^a   Xia, Yan ^b,c   Kim, Eun Kyung ^a   Jin, Yinglan ^b   Kaur, Navneet ^b   Kim, Eun Seon ^a   Kim, Dae Kyong ^a   Jung, Hwa Young ^d   Choi, Yongseok ^d   Park, Mi Kyung ^e   Min, Yong Ki ^e   Lee, Kiho ^b   Lee, Kyeong ^b,c  

^a Chung Ang University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c University of Science and Technology (UST)   (South Korea)

^d Korea University   (South Korea)

^e Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

ABC transporter; Adamantane; CYP3A4; MES SA DX5; Multidrug resistance; P glycoprotein

Indexed keywords

1 ADAMANTANECARBOXYLIC ACID; 3 TRIFLUOROPHENYL DERIVATIVE; ADAMANTANE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450 3A4; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; PACLITAXEL; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; STRUCTURE ACTIVITY RELATION;

ADAMANTANE; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; SARCOMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68949132702     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.127     Document Type: Article

References (15)

1. For recent reviews, see:. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Nat. Rev. Drug Disc. 5 (2006) 219
2. Curr. Opin. Pharmacol. 2006, 6, 350.
3. Ozben T. FEBS Lett. 580 (2006) 2903
4. Longley D.B., and Johnston P.G. J. Pathol. 205 (2005) 275
5. Bisi A., Meli M., Gobbi S., Rampa A., Tolomeo M., and Dusonchet L. Bioorg. Med. Chem. 16 (2008) 6474
6. Pusztai L., Wagner P., Ibrahim N., Rivera E., Theriault R., Booser D., Symmans F.W., Wong F., Blumenschein G., Fleming D.R., Rouzier R., Boniface G., and Hortobagyi G.N. Cancer 104 (2005) 682
7. Wadkins R.M., and Houghton P.J. Biochemistry 34 (1995) 3858
8. Colotta V., Catarzi D., Varano F., Calabri F.R., Lenzi O., Filacchioni G., Martini C., Trincavelli L., Deflorian F., and Moro S. J. Med. Chem. 47 (2004) 3580
9. Ech-Chahad A., Minassi A., Berton L., and Appendino G. Tetrahedron Lett. 46 (2005) 5113
10. 5 689.3077, found 689.3077.
11. 5 648.2811, found 648.2811.
12. Michael M., and Doherty M.M. J. Clin. Oncol. 23 (2005) 205
13. Zhou S.F., Di Y.M., Chan E., Du Y.M., Chow V.D., Xue C.C., Lai X., Wang J.C., Li C.G., Tian M., and Duan W. Curr. Drug Metab. 9 (2008) 738
14. van Schaik R.H. Drug Resist. Updat. 11 (2008) 77
15. 4 cells/well in 100 μl of medium and incubated for 24 h at 37 °C. The cells were then treated with varying concentrations of a test compound in the presence or absence of 100 nM Taxol for 60 h. Then, cell survival was assayed using Cell Counting Kit-8 (dojindo). Reversal of MDR is indicated if the compound enhances the toxicity of Taxol against MES-SA/DX5 cells.